BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22300685)

  • 1. Stopping menopausal hormone therapy: if breast cancer really decreased, why did colorectal cancer not increase?
    Nahum GG; Stanislaw H; Simon JA
    Maturitas; 2012 Apr; 71(4):354-9. PubMed ID: 22300685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
    Simon JA; Nahum GG; Stanislaw H; Gaines T
    Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of changes in hormone therapy on breast cancer incidence in the US population.
    Coombs NJ; Cronin KA; Taylor RJ; Freedman AN; Boyages J
    Cancer Causes Control; 2010 Jan; 21(1):83-90. PubMed ID: 19795215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and benefits of hormone therapy: has medical dogma now been overturned?
    Shapiro S; de Villiers TJ; Pines A; Sturdee DW; Baber RJ; Panay N; Stevenson JC; Mueck AO; Burger HG
    Climacteric; 2014 Jun; 17(3):215-22. PubMed ID: 24654673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users.
    Gambrell RD; Maier RC; Sanders BI
    Obstet Gynecol; 1983 Oct; 62(4):435-43. PubMed ID: 6888821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen plus progestin and colorectal cancer in postmenopausal women.
    Chlebowski RT; Wactawski-Wende J; Ritenbaugh C; Hubbell FA; Ascensao J; Rodabough RJ; Rosenberg CA; Taylor VM; Harris R; Chen C; Adams-Campbell LL; White E;
    N Engl J Med; 2004 Mar; 350(10):991-1004. PubMed ID: 14999111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal hormone therapy and breast cancer.
    Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II.
    Hildebrand JS; Jacobs EJ; Campbell PT; McCullough ML; Teras LR; Thun MJ; Gapstur SM
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2835-41. PubMed ID: 19843681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer.
    La Vecchia C
    Breast; 2004 Dec; 13(6):515-8. PubMed ID: 15563861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S
    Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
    Li CI; Malone KE; Daling JR
    Cancer Causes Control; 2006 Jun; 17(5):695-703. PubMed ID: 16633917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy?
    Gompel A; Plu-Bureau G
    Ann N Y Acad Sci; 2010 Sep; 1205():268-76. PubMed ID: 20840283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States).
    Aiello EJ; Buist DS; White E
    Cancer Causes Control; 2006 Dec; 17(10):1227-35. PubMed ID: 17111253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.